nad+ dosage: Frequently asked questions

Verify your dosage is within the therapeutic range (250–500mg oral precursors daily) and that you're using a precursor compound. Not oral NAD+ itself. Check timing: are you dosing in the morning within 2–4 hours of waking? NAD+ synthesis follows circadian rhythms, and mistimed supplementation can reduce efficacy by 40%. Consider adding cofactors. Riboflavin 400mg and magnesium 400mg support the enzymatic conversion steps that produce NAD+ from precursors. If baseline NAD+ levels were already high (common in individuals under 35 or those with exceptional metabolic health), marginal gains will be smaller and harder to detect without biomarker testing.

Most insurance plans do not cover NAD+ infusion as it remains classified as experimental treatment for addiction despite growing clinical evidence. Out-of-pocket costs range $300–$800 per 1000mg IV session, meaning a full 10-day acute protocol costs $3000–$8000. Some patients pursue oral NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) as lower-cost alternatives, though bioavailability is significantly lower. Oral NR at 500–1000mg daily produces 40–60% of the plasma NAD+ elevation seen with IV administration. If cost is prohibitive, prioritize IV NAD+ for the acute 10-day phase and transition to oral precursors for maintenance rather than skipping NAD+ therapy entirely.

NAD+ decline accelerates after age 60, but higher doses don't necessarily compensate better than standard therapeutic ranges. The rate-limiting factor isn't precursor availability. It's NMNAT enzyme expression, which declines with age. Start with 250mg NMN or NR daily and assess response over 8 weeks using subjective markers (energy, sleep quality, recovery) or objective biomarkers (blood NAD+ levels if accessible). If response is minimal, increase to 500mg daily before considering higher doses. Above 750mg daily, marginal returns diminish sharply regardless of age. IV NAD+ may be more effective for individuals over 65 due to declining oral absorption capacity and reduced gut transporter expression.

Begin with a modified acute loading protocol: 500–750mg IV daily for 7–10 days, then transition to maintenance dosing at 250mg every 10–14 days. Post-detox NAD+ is still effective because neuronal NAD+ depletion persists for 4–8 weeks after substance clearance. You're treating metabolic damage, not active withdrawal. Observational data shows patients starting NAD+ 1–2 weeks post-detox still achieve meaningful craving reduction and cognitive improvement, though the effect size is slightly smaller than protocols initiated during acute withdrawal (likely because some spontaneous NAD+ recovery has already occurred).

Nausea typically indicates rapid nicotinamide release triggering methyl donor depletion. Split the dose into 250mg twice daily rather than 500mg once. Flushing (facial warmth, tingling) results from nicotinic acid formation during NMN metabolism and resolves within 20–30 minutes; it's harmless but uncomfortable. If flushing persists despite dose splitting, switch to NR (nicotinamide riboside) which converts to NAD+ via a different enzymatic pathway that produces less nicotinic acid as a byproduct.

Increase to 1000mg daily and extend the trial to 8–12 weeks. DNA repair outcomes are not subjectively noticeable. PARP activation and base excision repair happen at the cellular level without producing energy shifts, mood changes, or other acute signals. The only way to confirm efficacy is through biomarker testing: 8-hydroxy-2'-deoxyguanosine (8-OHdG) in urine measures oxidative DNA damage; a reduction over 8–12 weeks indicates repair pathway activation. Whole blood NAD+ testing is available through specialty labs and confirms precursor absorption, though it doesn't directly measure nuclear repair activity.

Switch to sublingual administration at the same 500mg dose or increase oral dose to 750–1000mg. Oral bioavailability varies 10–15% between individuals based on gut microbiome composition and hepatic enzyme activity. Some people are poor converters who never achieve therapeutic NAD+ elevation from oral precursors regardless of dose. Sublingual delivery bypasses this variable entirely, and if sublingual 500mg still produces no benefit after eight weeks, the cognitive complaint likely lies outside NAD+-responsive pathways.

NAD+ levels at age 25–35 are typically 80–90% of physiological peak. Supplementation below age 40 shows minimal mitochondrial benefit unless baseline NAD+ is already compromised by chronic stress, sleep deprivation, or metabolic dysfunction. A Aging Cell (2024) trial found no significant improvement in mitochondrial respiration among healthy adults under 35 taking 300mg NMN daily for 12 weeks. If you're considering prophylactic NAD+ support, measure baseline NAD+ metabolites first. Supplementing without deficiency wastes money and risks disrupting endogenous synthesis feedback loops.

You're stacking two mechanisms. Direct NAD+ replacement and precursor-driven synthesis. Which may produce additive benefit in tissues with high salvage pathway activity. A small 2025 pilot study found 150mg sublingual NAD+ plus 300mg oral NR increased muscle NAD+ levels 28% more than either alone. The trade-off is cost and complexity. For research purposes exploring maximal NAD+ elevation, combination protocols are worth testing. For general energy support, sublingual NAD+ alone is more cost-effective.

You'll still absorb NAD+, but circadian timing reduces effectiveness by 30–40%. NAD+ biosynthesis via the salvage pathway operates on a clock-controlled cycle. NAMPT expression peaks in the morning and declines through the day. Evening NAD+ supplementation fights against this natural trough, meaning plasma elevation is blunted and clearance is faster. If morning dosing isn't feasible, early afternoon (before 2 PM) is the next-best window.

Verify fasted-state timing first. If you're dosing within four hours of eating, the NAD+/NADH ratio likely isn't high enough for sirtuin engagement. Second, confirm the product is genuinely NMN and not nicotinamide (a cheaper precursor that doesn't convert efficiently). Third-party testing matters. Our team sources compounds like MK 677 from facilities with batch-level purity verification because unlabeled substitution is common in the NAD+ precursor market. If timing and product quality are correct but results are absent, consider that individual CD38 expression varies widely. Some people degrade NAD+ 3× faster than others, requiring higher doses or CD38 inhibitors like apigenin to sustain levels.

This indicates rapid nicotinamide accumulation from excessive conversion. Start at 125mg and titrate up by 125mg weekly until reaching 250–500mg. Flushing occurs when nicotinamide is methylated to N-methylnicotinamide. A reaction that releases histamine in some individuals. Taking NMN with food slows absorption and reduces this spike. If flushing persists even at low doses, switch to NR, which produces less nicotinamide during conversion. Our team has found gradual dose escalation eliminates this response in 90% of cases within two weeks.

No. Start at mid-range (500mg sublingual or 250mg subcutaneous twice weekly) and escalate only if objective testing shows partial but incomplete response after eight weeks. Severe cognitive decline often involves multiple mechanisms (vascular insufficiency, neuroinflammation, protein aggregation) that NAD+ alone cannot address. Jumping to maximum dose without confirming NAD+ responsiveness wastes time and money when other interventions may be required. Dose escalation should always follow objective measurement, not subjective urgency.

Flushing indicates you're using niacin (nicotinic acid) rather than NMN or NR. Niacin triggers prostaglandin D2 release at doses above 50mg, causing the characteristic skin flush and warmth. Switch to NMN or NR, which don't activate this pathway. Nausea typically occurs with doses above 1,000mg daily or when taking precursors on an empty stomach in sensitive individuals. Split the dose (250mg morning, 250mg afternoon) or take with a small amount of food containing healthy fats to slow absorption. Liposomal formulations reduce GI irritation in approximately 70% of individuals who report standard capsule intolerance.

Reduce resveratrol to ≤250mg daily or separate dosing by 8–12 hours. The NNMT enzyme that clears excess nicotinamide also metabolises resveratrol; saturation at high doses (≥500mg resveratrol) may impair NAD+ precursor cycling. No human trial has tested this interaction directly, but the shared metabolic pathway suggests potential interference. If biomarker testing shows suboptimal NAD+ elevation despite adequate NR/NMN dosing, resveratrol is the first variable to adjust.

Yes, but precursor choice matters. NMN and NR do not increase homocysteine because they bypass the nicotinamide methylation step entirely. Straight nicotinamide supplementation above 500mg daily should be avoided or paired with methylated B-vitamins (methylfolate, methylcobalamin) to support homocysteine clearance. Baseline homocysteine testing before starting any NAD+ protocol is standard practice in longevity medicine.

Slow the infusion rate immediately. These are the most common side effects and correlate directly with infusion speed, not total dose. Reducing from 1000mg over 4 hours to 1000mg over 8 hours eliminates symptoms in 80% of cases without reducing efficacy. If symptoms persist, splitting the dose (500mg in the morning, 500mg in the evening) maintains therapeutic plasma levels while minimizing peak concentration. True NAD+ intolerance is rare. Most 'intolerance' is actually infusion rate sensitivity that resolves with protocol adjustment.

Avoid evening dosing. NAD+ precursors administered after 4pm can disrupt circadian rhythm and interfere with sleep onset. NAD+ activates SIRT1, which regulates circadian clock genes (CLOCK, BMAL1) that govern the sleep-wake cycle. Research published in Cell Metabolism found that NMN taken within four hours of bedtime delayed melatonin secretion by 45-60 minutes and reduced sleep efficiency. NAD+ levels naturally decline through evening to allow SIRT1 activity to decrease, permitting the transition to rest and repair states. Supplementing against this rhythm disrupts the metabolic program. Take your full daily dose before 3pm, split into two administrations if possible.

Reduce to 500mg and switch to sublingual delivery. Doses above 500mg saturate cellular uptake mechanisms. NMN transporters (Slc12a8 in humans) have finite capacity. Excess precursor is either excreted unchanged or converted to nicotinamide, which then competitively inhibits the very enzymes (sirtuins, PARPs) that NAD+ is supposed to activate. A study in Cell Reports (2023) found 1000mg oral NMN produced no greater intracellular NAD+ increase than 500mg, but doubled urinary nicotinamide metabolites. If you've been dosing oral capsules, the issue is likely bioavailability. Not insufficient quantity.

Discard them. Nicotinamide mononucleotide exposed to temperatures above 30°C for more than 6 hours loses 40–60% potency due to thermal degradation. The molecular structure remains visually identical. You can't tell by looking at the powder. But the biological activity is compromised. This is why research-grade suppliers ship with cold packs during summer months and guarantee temperature-controlled logistics. Retail brands rarely disclose shipping conditions, making summer purchases especially risky.